ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / GYRE
WVE (22) APMD (44) SGMT (45) DSGN (35) ⌘ Pro Terminal →

Gyre Therapeutics Inc. (GYRE) — RQD Stock Rating Cockpit

$4.56 -28.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.31

Gyre Therapeutics Inc. (GYRE) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $714.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GYRE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Gyre Therapeutics Inc. (NASDAQ: GYRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.56 (-28.94% 1D, market cap $714.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GYRE ranks #341 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GYRE compare to WVE and APMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GYRE carries a Roarable D (47/100 RQD), trailing P/E of 72.3x, gross margin of 95.4%, and ROIC of 25.4%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and APMD (Apnimed Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GYRE?
▼

Per GYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124105), Gyre Therapeutics Inc. generated $116.6M in revenue (+10.2% YoY), $9.9M in net income, and -$180.0K in free cash flow against $219.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.31 (-5.40%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (16)Whales (7)SEC (13)Macro (5)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$10 Bull$4 Base$3 Bear
📬 FREE GYRE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GYRE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY GYRE SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (34% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 95.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 14.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (49.8) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$6.87-11.4% Next Q
Q2 (-2Q)
52
Grade C-$6.09-0.3% Next Q
Q3 (-1Q)
50
Grade C-$6.07-24.9% Next Q
Current
47
Grade D$4.56-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GYRE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GYRE currently carries a cautious 47/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.72) and Max Pain ($4.79) forces dealer call-delta covering toward $9.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GYRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GYRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
49.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
14.33>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $5$4.56H: $9
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (95% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on GYRE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

25.4% ROIC with 95.4% gross margin and -0.03% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 14.33 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

13/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like GYRE
  • ✓Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Priced at 72x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GYRE)

  • ✓Walkthrough of GYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.42%▼ SUPPORT BREAKDOWN
2026-11-02O $7.09H $7.09L $4.56C $4.56VOL 185.3K
RES: $8.14SUP: $5.34SMA50: $6.72SMA200: $6.98
$8.34$7.30$6.27$5.23$4.20RES $8.14SUP $5.34$4.562026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GYRE Butterfly Map → + Track GYRE →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
46.8%/yr Implied 5Y Growth

vs. +10.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GYRE)

Health Care Rank #341 of 1016 ⚔️ WVE vs GYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GYRE vs. WVE, APMD, SGMT, DSGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Gyre Therapeutics Inc. (GYRE) ranks #341 by composite RQD confidence (47/100, grade D) and #398 by equity capitalization ($714.8M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. GYRE currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GYRE ACTIVE
Gyre Therapeutics Inc.
D 47/100 72.3x 95.4% 25.4% -28.94% $714.8M Benchmark Subject
WVE
Wave Life Sciences Inc.
E 22/100 — — -35.0% -1.10% $715.9M /wve-vs-gyre →
APMD
Apnimed Inc.
D 44/100 — — — -5.42% $721.9M /apmd-vs-gyre →
SGMT
Sagimet Biosciences Inc. (Series A)
D 45/100 — — -35.0% -4.89% $735.7M /sgmt-vs-gyre →
DSGN
Design Therapeutics Inc.
D- 35/100 — — -32.1% -3.44% $692.2M /dsgn-vs-gyre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001124105

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gyre Therapeutics Inc. (GYRE) reported GAAP revenue of $116.6M (+10.2% vs. FY2024 revenue of $105.8M , and +2.8% cumulative change since FY2023) , GAAP net income of $9.9M, operating cash flow of $1.0M, and free cash flow of -$180.0K (+97.0% YoY). On the balance sheet, GYRE closed FY2025 with $219.8M in total assets against $0 in total debt (Altman Z-Score: 14.33, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $116.6M $9.9M $1.0M -$180.0K $219.8M —
FY2024 (FY) 2024-12-31 $105.8M $17.9M -$3.6M -$6.0M $125.4M —
FY2023 (FY) 2023-12-31 $113.5M -$85.5M $25.9M $25.9M — —

3. GYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Gyre Therapeutics Inc. (NASDAQ: GYRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.56 (-28.94% 1D, market cap $714.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GYRE ranks #341 in composite RQD confidence.

How does GYRE compare to WVE and APMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GYRE carries a Roarable D (47/100 RQD), trailing P/E of 72.3x, gross margin of 95.4%, and ROIC of 25.4%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and APMD (Apnimed Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GYRE?

Per GYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124105), Gyre Therapeutics Inc. generated $116.6M in revenue (+10.2% YoY), $9.9M in net income, and -$180.0K in free cash flow against $219.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (95% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

GYRE last traded at $4.56 (-28.94% on volume of 394,091 shares), positioning the stock -32.14% below its 50-day simple moving average ($6.72) and -34.67% below its 200-day simple moving average ($6.98). Across its 52-week range of $4.52 to $9.14, GYRE sits at the 0.9% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.99 to $5.13).

GYRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GYRE stock right now?

Gyre Therapeutics Inc. (GYRE) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at 72x P/E (25% return on capital) under elevated 10-year interest-rate pressure.

What is GYRE's 12-month price target and RQD AI Jury consensus?

GYRE's 12-month base price target is $4.33 (range $3.38 to $9.6), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GYRE RQD Cockpit GYRE 12M Forecast GYRE Earnings & Move GYRE Dividends & DRIP GYRE Insiders & 13F GYRE Whale Options GYRE Profit Sankey GYRE News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GYRE — Gyre Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:33:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GYRE carries an RQD Score of 47 and a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars:

  • Fundamental Cash Engine: 16 / 20. Per the RQD rating, ROIC is 25.4% and FCF yield is -0.03%. The strong return on invested capital is offset by negative free cash flow yield, meaning the business's reported economics are not converting into cash returned to shareholders at current prices.
  • Whale / 13F Flow: 7 / 20. Per the RQD rating, institutional accumulation and options positioning score weakly. Holder-level detail is not available in source data, so the drivers of this score cannot be independently verified here.
  • Insider Conviction: 6 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly. Specific transactions are not itemized in the source data.
  • Macro Regime Fit: 5 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity scored low. This pillar carries the lowest weight of favorable inputs and indicates limited regime-based tailwind.
  • Forensic Balance Sheet: 13 / 20. Per the RQD rating, Altman Z is 14.33, Piotroski F is 5/9, and Debt/Equity is 0.5. The balance sheet metrics are the most supportive component of the score, though the Piotroski reading is mid-range rather than strong.

For a prospective investor, the rating reads as a warning rather than an endorsement. The strongest pillar (fundamentals) is undercut by negative FCF yield and a 72.3 trailing P/E, while the signal pillars (whale flow, insider conviction, macro fit) all score in the lower range. The valuation tradeoff is that the market is pricing substantial future earnings growth relative to the trailing EPS of 0.09. Upside would require sustained earnings expansion and cash conversion; the rating itself flags distribution risk rather than accumulation.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
6.41$714.8M72.367.253.30.090%1.0$4.52 - $9.1425.4%

Business

Gyre Therapeutics Inc. (GYRE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it carries a market capitalization of $0.7B. Source data does not detail specific products, customer segments, or revenue model beyond reported financial results.

Recent Catalysts & News Wire Analysis

  • Employment agreements (MARKET WIRE, YELLOW): Per the news feed, Gyre signed new employment agreements with CEO Ying Luo and CFO Thomas Eastling. This is a governance item rather than an operating catalyst.
  • Incyte reference (CATALYST, GREEN): Per the news feed, a Yahoo Finance item covers Incyte (INCY) reporting a Q3 loss and beating revenue estimates. This is a peer item tagged to GYRE; no direct linkage to GYRE operations is stated in source data.
  • One-day drop (RISK WATCH, RED): Per the news feed, Quantisnow lists GYRE among top stock losers, consistent with the -9.59% change in market data.
  • TG Therapeutics reference (MARKET WIRE, YELLOW): Per the news feed, a Trefis item covers TG Therapeutics' stock climb. This is a sector-adjacent item with no stated GYRE link.
  • Second employment agreement (MARKET WIRE, YELLOW): Per an SEC filing item in the feed, Gyre entered an employment agreement with Ying Luo as CEO.
  • Price action (MARKET WIRE, YELLOW): Per a feed item, GYRE climbed 6.10% to $6.44 with buyers testing the upper range. This item's source label is unreliable and conflicts with the current -9.59% move in market data; treat with caution.

Per the butterfly supply-chain graph, supply_chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's specific products, pipeline status, and revenue drivers behind the FY 2025 revenue of $116.6M?
  • Why is FCF negative in FY 2025 ($-0.2M) despite positive net income of $9.9M, and what is the cash conversion outlook?
  • Which institutional and insider transactions underlie the whale flow (7/20) and insider conviction (6/20) pillar scores?
  • What is total debt, given that debt is not reported in the financials despite a Debt/Equity of 0.5?
  • What drove the FY 2023 net loss of $-85.5M, and does that history affect the forensic balance sheet assessment?

GYRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gyre Therapeutics Inc. (GYRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GYRE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GYRE Bull vs. Bear Conversation Board — What's Your Call at $4.56?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GYRE 🐻 50% BEARISH CONVICTION
1. Pick Your Side on GYRE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $6.92 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GYRE (D • RQD 47/100) a Buy at $6.41?

Welcome to the GYRE (Gyre Therapeutics Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (25.4% ROIC), while bears focus on valuation multiple compression (72.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.94 (-22.9%)
Spot @ $6.41

Pump the brakes on GYRE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GYRE, but look at what you are paying: 72.3x trailing P/E with 95.4% gross margins. Unless Gyre Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.76 (+21.1%)
Spot @ $6.41

GYRE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GYRE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.41 (52-wk range $4.52 - $9.14), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%